Arthur Kirsch
Director/Board Member presso LIQUIDIA CORPORATION
Patrimonio netto: 472 000 $ in data 31/03/2024
Profilo
Arthur S.
Kirsch is currently an Independent Director at Liquidia Technologies, Inc., Liquidia Corp., and Anavasi Diagnostics.
He previously served as President & CEO at Natwest Securities Corp., Executive Vice President & Head-Equity Division at Drexel Burnham Lambert, Inc., President at NatWest Securities Ltd., Executive Vice President & Head-Research at Vector Securities LLC, and MD, Head-Healthcare Research & Capital Markets at Prudential Vector Healthcare Group.
He was also Chairman at POZEN, Inc., Independent Chairman at Old API Wind-down Ltd., and Independent Director at Immunomedics, Inc. and Kadmon Holdings, Inc. Mr. Kirsch holds an undergraduate degree from the University of Rhode Island and an MBA from Baruch College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
LIQUIDIA CORPORATION
0.04% | 21/11/2023 | 32 000 ( 0.04% ) | 472 000 $ | 31/03/2024 |
Posizioni attive di Arthur Kirsch
Società | Posizione | Inizio |
---|---|---|
LIQUIDIA CORPORATION | Director/Board Member | 28/06/2020 |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Director/Board Member | 13/12/2016 |
Anavasi Diagnostics | Director/Board Member | 02/11/2022 |
Precedenti posizioni note di Arthur Kirsch
Società | Posizione | Fine |
---|---|---|
KADMON HOLDINGS, INC. | Director/Board Member | 01/11/2021 |
OLD API WIND-DOWN LTD. | Chairman | 30/05/2019 |
IMMUNOMEDICS, INC. | Director/Board Member | 13/10/2016 |
POZEN INC. | Chairman | 05/02/2016 |
Vector Securities LLC
Vector Securities LLC Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Vector Securities LLC is a private company that provides investment banking services. The company is based in Deerfield, IL. Vector Securities was acquired by Prudential Securities on June 09, 1999. | Chief Tech/Sci/R&D Officer | 01/05/2004 |
Formazione di Arthur Kirsch
University of Rhode Island | Undergraduate Degree |
Baruch College | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
LIQUIDIA CORPORATION | Health Technology |
Aziende private | 12 |
---|---|
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
POZEN, Inc.
POZEN, Inc. Pharmaceuticals: MajorHealth Technology POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC. | Health Technology |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
PhysioSonics, Inc.
PhysioSonics, Inc. Medical DistributorsDistribution Services PhysioSonics, Inc. developed neurological medical devices. The firm offered products such as transcranial doppler and neuromonitor. It also developed ultrasound for automated monitoring of stroke symptoms. The company was founded in 2000 and was headquartered in Bellevue, WA. | Distribution Services |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Drexel Burnham Lambert, Inc. | Process Industries |
NatWest Securities Ltd. | Finance |
Vector Securities LLC
Vector Securities LLC Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Vector Securities LLC is a private company that provides investment banking services. The company is based in Deerfield, IL. Vector Securities was acquired by Prudential Securities on June 09, 1999. | Finance |
Natwest Securities Corp. | |
Prudential Vector Healthcare Group | Finance |
Old API Wind-down Ltd.
Old API Wind-down Ltd. Pharmaceuticals: MajorHealth Technology Aralez Pharmaceuticals Inc. engages in the development, acquisition, and commercialization of cardiovascular, pain, and other product therapies. It operates through the following geographical segments: United States and Canada. The company is founded on December 2, 2015, and is headquartered in Mississauga, Canada. | Health Technology |
Anavasi Diagnostics |
- Borsa valori
- Insiders
- Arthur Kirsch